Novakand Pharma AB (publ) (STO:NOVKAN)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.103
-0.021 (-17.04%)
Mar 9, 2026, 4:56 PM CET
-93.20%
Market Cap 15.08M
Revenue (ttm) n/a
Net Income (ttm) -47.23M
Shares Out 121.19M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 476,885
Average Volume 676,042
Open 0.115
Previous Close 0.124
Day's Range 0.102 - 0.130
52-Week Range 0.075 - 2.250
Beta 0.92
RSI 43.96
Earnings Date Feb 20, 2026

About Novakand Pharma AB

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in Septembe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol NOVKAN
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.